Documentation RequiredProvider Action Callout
• Testing modality and documentation: Providers must document the specific assay and specimen type used when ordering STI testing. Authorization and coverage determinations may be affected if the medical record does not state the testing method (e.g., NAAT, PCR, culture, EIA) and the specimen source (eg, first-catch urine, endocervical swab, vaginal swab, pharyngeal swab, rectal swab, lesion exudate, serum, CSF). Laboratory reports should include the FDA clearance/510(k) or PMN identifier when available.
• Applicable procedure codes (billing requirement): When submitting claims, include the applicable CPT/HCPCS codes that correspond to the performed assay. Use the code that matches the specific assay performed (eg, organism-specific NAAT CPT codes, multiplex STI panel codes, culture/susceptibility codes). Omitted or incorrect coding may lead to claim denial or request for additional clinical documentation.
• Specimen and assay match: The specimen type must be appropriate for the assay per manufacturer instructions and guideline recommendations (eg, NAATs validated for urine vs extragenital swabs; syphilis serology requires serum). Claims for assays performed on non-validated specimen types may be denied.
• NAAT requirement for chlamydia and gonorrhea screening: For routine screening and diagnosis of C. trachomatis and N. gonorrhoeae, NAAT (FDA-cleared/validated) is the required modality unless otherwise specified (eg, culture when antimicrobial susceptibility is needed). Document rationale if an alternate method is used.
• Syphilis testing sequencing and confirmatory testing: Syphilis coverage requires serologic testing using both treponemal and nontreponemal tests as indicated. Use the recommended sequencing (standard or reverse algorithm) and perform reflex quantitative NTT when appropriate. A single serologic test (only treponemal OR only nontreponemal) is insufficient for diagnosis and may be non-covered without follow-up testing and documentation. If primary screen is positive, perform confirmatory testing or reflex testing per guidelines (eg, reflex quantitative RPR/VDRL and/or TPPA/TPHA) and document results and clinical interpretation.
• Syphilis PCR/NAAT: PCR/NAAT for T. pallidum is not covered for routine diagnosis (not FDA-approved commercially); if used, document clinical justification and note any conflict with coverage guidance. Darkfield microcopy or validated lesion NAAT performed in specialized settings should be documented with laboratory validation data.
• Conflict with government policy: If an ordering clinician follows a governmental or public-health directive (eg, CDC/health department outbreak response, mandated public health testing), document the directive and relevant guidance in the chart to support coverage; such directives may supersede routine coverage rules.
• Clinical documentation to support coverage: For all covered indications, include clinical signs/symptoms, risk factors, timing (eg, screening frequency for PrEP, MSM, HIV-positive individuals), and treatment history when relevant (eg, treatment failure, test-of-cure). For tests of cure, document prior positive test and treatment date.
• Assay and specimen documentation: Laboratory reports accompanying claims should state assay name, manufacturer, FDA 510(k) or PMN when available, specimen source, collection date/time, and whether the assay is qualitative or quantitative. For multiplex or panel assays, include which targets were tested and reported.
• References and device authorization: When relevant, include reference to FDA 510(k) clearance or PMN numbers for commercial assays in the medical record or laboratory report. Coverage decisions reference FDA-cleared assays (eg, Cepheid Xpert CT/NG, Abbott Alinity m STI, BD Onclarity) and guideline-endorsed methods.
• Gonorrhea treatment failure and susceptibility testing: For individuals not responding to recommended therapy, culture with antimicrobial susceptibility testing for N. gonorrhoeae meets coverage criteria and should be ordered; document prior treatment regimen, clinical course, and reason for susceptibility testing. NAAT-based resistance testing does not meet coverage criteria and is not covered.
• Step therapy: There are no step therapy requirements for STI diagnostic testing described in this policy. If any formulary or treatment step is relevant to antimicrobial management, document clinical justification for deviation from standard therapy.
• Consider near-patient NAATs prior to empiric treatment: When available and clinically appropriate, consider use of near-patient (POC) NAAT to guide therapy to reduce unnecessary empiric treatment; document test availability, result, and how it informed management.
• Testing method sequencing and reflex rules: Follow the sequencing and reflex rules described in policy and CDC guidance (eg, reflex quantitative NTT when TT positive; reflex TT when NTT primary screen positive; perform NAAT on appropriate anatomical site when extragenital exposure suspected). Document reflex testing performed and clinical interpretation.
- Document assay name, manufacturer, and FDA 510(k)/PMN when available in lab report and medical record.
- Include appropriate CPT/HCPCS codes that match the specific assay performed on the claim.
- Ensure specimen type is validated for the ordered assay; do not submit tests performed on non-validated specimens without justification.
- Use NAAT (FDA-cleared/validated) for chlamydia and gonorrhea screening and diagnosis unless culture for susceptibility is clinically indicated.
- For syphilis, do not rely on a single serologic test; perform and document treponemal and nontreponemal testing per algorithm and reflex quantitative NTT or confirmatory TT as required.
- If testing conflicts with governmental/public-health directives, document the directive and rationale.
- For possible gonorrhea treatment failure, order culture for susceptibility and document prior treatment; NAAT-based resistance testing is not covered.
- Consider near-patient NAATs where available before empiric therapy to improve antimicrobial stewardship.